Clinical Trials Browser

Phase 3 × osimertinib × 90 days × Clear all

NCT04351555 2026-06-05

NeoADAURA

Phase 3 Active not recruiting

358 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT04181060 2026-06-03

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT05015608 2026-05-27

SACHI

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT06417814 2026-05-14

TROPION-Lung15

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT06486142 2026-05-14

ERIS

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07376382 2026-05-13

SYNSTAR-02

Phase 3 Not yet recruiting

NSCLC

NCT04487080 2026-05-08

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT06670196 2026-05-08

A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06350097 2026-05-06

TROPION-Lung14

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03521154 2026-05-05

LAURA

Phase 3 Active not recruiting

216 enrolled 25 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05624996 2026-05-04

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT05120349 2026-04-23

ADAURA2

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02296125 2026-04-21

FLAURA

Phase 3 Completed

674 enrolled 21 charts 1 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT04765059 2026-04-21

COMPEL

Phase 3 Active not recruiting

98 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT06838273 2026-04-20

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05261399 2026-04-06

SAFFRON

Phase 3 Active not recruiting

Carcinoma, Neoplasm Metastasis

NCT05629234 2026-04-06

ROSY-T

Phase 3 Active not recruiting

Neoplasms

NCT02511106 2026-03-30

ADAURA

Phase 3 Active not recruiting

682 enrolled 20 charts 1 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma